Kim Coghill

WASHINGTON - Former ImClone Systems Inc. CEO Samuel Waksal has been subpoenaed by a House subcommittee to answer questions surrounding the business transactions and development of the investigational cancer drug Erbitux. (BioWorld Today)

Waksal Subpoenaed; ImClone To Face House Subcommittee

June 6, 2002

By Kim Coghill

WASHINGTON - Former ImClone Systems Inc. CEO Samuel Waksal has been subpoenaed by a House subcommittee to answer questions surrounding the business transactions and development of the investigational cancer drug Erbitux. (BioWorld Today)

Synthetic Blood Gains Access To $20M Equity Credit Line

June 4, 2002

By Kim Coghill

Articles by Kim Coghill

Elan To Narrow Drug Focus, Tighten Governance Practice

Albany Molecular Enters Deal With Merck For Chemistry Work

Albany Molecular Enters Deal With Merck For Chemistry Work

Roche Invests $20M In Genmab In Expansion Of Antibody Alliance

Senators Seeking Compromise On Legislation To Ban Cloning

Roche Invests $20M In Genmab In Expansion Of Antibody Alliance

Senators Seeking Compromise On Legislation To Ban Cloning

Waksal Subpoenaed; ImClone To Face House Subcommittee

Waksal Subpoenaed; ImClone To Face House Subcommittee

Synthetic Blood Gains Access To $20M Equity Credit Line

Today's news in brief

News in brief

Axsome’s Auvelity cleared for large Alzheimer’s agitation market

Sonire starts US study of cancer HIFU after $18M series A

Coreterra Therapeutics patents agents for schizophrenia